Treatment - Page 39 of 471 Posts on Medivizor

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Posted by Medivizor on Sep 5, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...

Evaluating the impact of brain metastasis in the effectiveness of immunotherapy in patients with non-small cell lung cancer

Posted by Medivizor on Sep 5, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of immune checkpoint inhibitors (ICI) versus chemotherapy in patients with non-small cell lung cancer (NSCLC) andy brain metastases (BM). The data showed that the effectiveness of ICIs was similar in patients with no BM symptoms and/or treated BMs. For patients with BMs, ICI combination therapy was...

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by Medivizor on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Posted by Medivizor on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib. Some background Chronic lymphocytic...

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Posted by Medivizor on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...

Evaluating the effectiveness and safety of different bevacizumab schedules in combination with chemotherapy for the treatment of patients with metastatic colorectal cancer.

Posted by Medivizor on Aug 29, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) administered either on the same day or a few days before chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab administered 4 days before chemotherapy significantly improved overall survival with...

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Posted by Medivizor on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to...

Comparing TURP and laser prostate surgery for benign prostatic hyperplasia in older patients and those with multiple medical conditions

Posted by Medivizor on Aug 29, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study compared the safety and effectiveness of transurethral resection of the prostate (TURP) and laser prostate surgery in older patients and those with multiple medical conditions. The data showed that compared to laser surgery, TURP had a lower risk of needing further surgery but higher complications rates in these...

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Evaluating the effectiveness and safety of ciltacabtagene autoleucel for the treatment of patients with unresponsive multiple myeloma.

Posted by Medivizor on Aug 29, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these...

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Posted by Medivizor on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...

Treating classic Hodgkin lymphoma in children – a guideline

Posted by Medivizor on Aug 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell These guidelines reviewed current recommendations on treating newly diagnosed classic Hodgkin lymphoma (cHL) in children and young adults, and cHL which has returned after previous treatment. Some background Hodgkin lymphoma is cancer of the lymph nodes, which are part of the immune system. It involves cancerous versions of B cells,...

Treatment Posts on Medivizor

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Evaluating the impact of brain metastasis in the effectiveness of immunotherapy in patients with non-small cell lung cancer

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Evaluating the effectiveness and safety of different bevacizumab schedules in combination with chemotherapy for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Comparing TURP and laser prostate surgery for benign prostatic hyperplasia in older patients and those with multiple medical conditions

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ciltacabtagene autoleucel for the treatment of patients with unresponsive multiple myeloma.

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Treating classic Hodgkin lymphoma in children – a guideline

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email